- Home
- EBS vs KALV Comparison
EBS vs KALV Comparison
Compare EBS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- KALV
- Stock Information
- Founded
- EBS 1998
- KALV N/A
- Country
- EBS United States
- KALV United States
- Employees
- EBS N/A
- KALV N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- KALV Health Care
- Exchange
- EBS Nasdaq
- KALV Nasdaq
- Market Cap
- EBS 359.3M
- KALV 796.4M
- IPO Year
- EBS 2006
- KALV N/A
- Fundamental
- Price
- EBS $7.91
- KALV $13.61
- Analyst Decision
- EBS Strong Buy
- KALV Strong Buy
- Analyst Count
- EBS 3
- KALV 8
- Target Price
- EBS $14.33
- KALV $26.43
- AVG Volume (30 Days)
- EBS 926.9K
- KALV 984.5K
- Earning Date
- EBS 11-05-2025
- KALV 09-11-2025
- Dividend Yield
- EBS N/A
- KALV N/A
- EPS Growth
- EBS N/A
- KALV N/A
- EPS
- EBS 2.53
- KALV N/A
- Revenue
- EBS $851,600,000.00
- KALV $1,426,000.00
- Revenue This Year
- EBS N/A
- KALV N/A
- Revenue Next Year
- EBS $19.24
- KALV $213.43
- P/E Ratio
- EBS $3.12
- KALV N/A
- Revenue Growth
- EBS N/A
- KALV N/A
- 52 Week Low
- EBS $4.02
- KALV $7.30
- 52 Week High
- EBS $12.73
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- EBS 48.01
- KALV 45.86
- Support Level
- EBS $7.75
- KALV $13.35
- Resistance Level
- EBS $8.13
- KALV $14.25
- Average True Range (ATR)
- EBS 0.37
- KALV 1.02
- MACD
- EBS -0.08
- KALV -0.16
- Stochastic Oscillator
- EBS 39.32
- KALV 9.38
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.